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Abstract
Kidney disease increasingly impacts people with cystic fibrosis (CF) as adult patients continue to survive longer. Yet the
literature on CF related kidney disease focuses little on amplifying the voices of people aging with the condition. This
article presents perspectives on CF related kidney disease from a medical sociologist who is themselves managing these
issues. It (1) gives an overview of relevant literature and trends in epidemiological data on kidney disease and CF, (2)
details the author’s own process of adjusting to progressive changes in renal function, and (3) outlines opportunities for
clinicians to make a positive impact for patients by centering their voices.
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Introduction
My kidneys and I recently celebrated 34 years of life—a
milestone that might have seemed unrealistic had I been
born in a different time. It seemed out of reach for me as
well until I began getting coordinated care for my cystic
fibrosis (CF), a disease that has likewise spent all 34 years
with me but only received proper management well into
my adult years. CF is a genetic disease in which the body
cannot produce, transport, and/or use a specific type of
protein that helps electrolytes get across cell membranes1.
It remains the most common fatal genetic disease among
people of European heritage2. Surviving and beginning to
thrive with my CF has thus involved reckoning with many
things beyond my own mortality as a general construct.
Like any other patient, I constantly engage in illness
management—the process of adjusting to changes in my
health and allowing them to become part of my sense of
normalcy3. And like any other scientist, I generally begin
my processes of reckoning by examining data. In this
narrative, I use my experiences to (1) give an overview of
scholarship related to CF and kidney disease, (2) detail my
experiences managing CF and kidney disease, and (3)
outline ways clinicians can better serve patients by
amplifying our voices.

An Overview of Scholarship on CF and Kidney
Disease
Throughout my 34 years and counting, some trends in CF
survival data have remained remarkably similar. Over 80
percent of people with CF still die from respiratory failure,
even if they live for many decades before their lungs
eventually succumb to the ravages of the disease4. That

leaves the other 20 percent of us who will likely still die
from our CF, but from impacts to other organ systems as
opposed to steep declines in lung function5. Kidney
disease increasingly ranks among the leading causes of
death for adults with CF6. This represents a change in the
data from the early 1980s when I was born. My
nephrologist here in Orlando commented that the learning
curve for physicians has been just as steep as it has for
patients with respect to chronic kidney disease, as only
recently did people with CF begin surviving long enough
in sufficient numbers to present a substantial case
population.
Kidney disease is not a universal experience among people
with CF, in part because so many patients continue to
experience respiratory failure. The unique form of diabetes
associated with CF can also harm the kidneys, but is
observed in under 50 percent of the total disease
population7. Likewise, not everyone who does develop CF
related diabetes experiences kidney dysfunction as a
result8. However, every person living with CF does
experience elevated risk for renal impairment, especially as
they grow older9. Several factors can contribute to kidney
disease in people aging with CF. One prominent factor is
obstruction of the glomeruli—the small ducts inside of the
kidneys that transport fluids—with hardened pieces of
mucus10. While I return to other pieces of CF or kidney
disease where relevant later in the piece, these examples
represent the overall picture of the intersection of these
conditions in the existing scholarship. With this
background in mind, I now shift to my own experiences
before drawing on those experiences to make suggestions
for clinicians in closing.
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My Experience with CF and Kidney Disease
Years before my pulmonologist would ask how all my
doctors in New Jersey never recognized these “casts” in
my urine for what they were, I would stand beneath the
lighting fixture in my parents’ kitchen as we all peered at a
jam jar full of my urine. My mother and father, with PhDs
in neuroscience and cell biology respectively and a
collective four decades of experience as medical educators,
were just as mystified as I was by the glowing white
threads that floated in the liquid. Although we all spared a
moment to appreciate the humor of collecting a urine
specimen in a dainty little gingham-topped jar, there was
also a sense of foreboding. Two years prior, I had been
admitted to intensive care with a tentative diagnosis of
renal failure.
Further testing—including the singularly peculiar
experience of collecting all of my urine and feces for 24
hours while trying not to trip over my intravenous pole or
drop my heart monitor into the toilet—revealed that my
kidneys were stressed but responding as best they could to
problems with other systems. The next time I was able to
speak to my mother, who had frantically offered to give
me one of her kidneys as my father haggled with airline
ticket agents, I told her to keep her organs for the time
being. With a serum potassium of 2.1 milliequivalents per
liter that refused to budge even after oral supplements
were introduced on top of the IV, I found humor where I
could. But the laughter faded quickly as it became clear
that the specter of kidney disease had long since become
reality.
I spent years shuttling around to various nephrologists,
first in central New Jersey and then in northern Florida as
my increasing intolerance to cold drove me southward.
Raynaud’s syndrome manifested early—a consequence of
the vascular damage increasingly seen in adults with CF as
survival increases11. I wound up in Orlando, where care
options for adults with CF are markedly better, through a
combination of persistence and serendipity when FSU
College of Medicine offered me a transfer to the Regional
Campus here in exchange for my commitment to build out
our community partnerships for aging research in the area.
I enthusiastically accepted what amounted to a dream
come true with no small sense of the irony inherent in it—
someone with what remains a decidedly terminal illness
leading research efforts centered around healthy aging. Yet
that became an important milestone in my adaptation to
living with the impacts of my CF, which at that point had
been diagnosed conclusively, initiating a good deal of
scrambling by myself and a vast team of clinicians to
compensate for lost time.
Indeed, one of the other common causes of kidney
damage in people with CF contributed strongly to the
conversion of my diagnosis from a lifelong suspicion to a
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formal pronouncement. I moved down to Orlando with a
raging bacterial infection that had spread through my
entire renal and urinary system. Such infections often
spiral out of control in people whose CF is inadequately
managed, as mine was for the better part of three decades.
Paradoxically, some of the more aggressive drug therapies
used for CF can also make the kidneys more vulnerable to
bacterial colonization12. I fell victim to this truism as well
when ranitidine, a medication intended to reduce my
gastrointestinal symptoms, aggravated my kidney issues so
much that my entire lower body broke out in vasculitis
rashes. A quick literature search revealed that vascular
complications associated with kidney inflammation tend to
occur more often in CF patients with substantial
autoimmunity13 as already documented in my own medical
records. I showed up at my primary care doctor’s office in
Tallahassee, passed him a series of pictures on my phone,
and said “I have Henoch-Schoenlein purpura”. Although
this was far from a good day, it paved the way for much
better ones to follow.
Months later, my new nephrologist would gently diagnose
me with chronic kidney disease—“but only Stage 1, we still
have plenty of time”—and send me off for a
comprehensive renal and urinary ultrasound. While I
waited for the results, I spent a lot of time thinking back to
that day in the hospital when I told my mother to keep her
kidneys, and all the times we had argued since about
whether or not I should list for a transplant if my own
failed. I thought about my pulmonlogist’s confidence that
by a combination of atypical genetics and hard work, I
might survive long enough for my CF to become largely
irrelevant for my life expectancy. Combing through
endless arrays of literature and data, I concluded that
although this was an outcome I very much wanted for
myself and my family, getting there might require difficult
decisions about my willingness to consider organ
transplantation.
This meant that I needed types of data that are often more
difficult to find in research journals—those that amplify
patient voices and experiences14. I knew plenty of people
with double lung transplants, something that had never
been on the table for me once inhaled corticosteroids had
rescued my pulmonary function15. As I got more involved
in the CF community online, I also came to know several
people who had undergone successful kidney transplants.
Some of them even had stories like mine—relatively
classic phenotypic cases of CF that fell through the cracks
in a broken health care system. My first chloride sweat
tests, once the gold standard for diagnosing CF, were
performed at a scant few years of age. Insufficient sweat
meant no conclusive diagnosis despite concerning results,
and I floundered into adulthood with a halfway managed
disease playing havoc with my body. I lost upwards of 40
pounds from my slender frame that I would never find
again. I lived with chronic mycobacterial pneumonia for
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most of my 20s. My kidneys screamed with pain daily. My
legs swelled, the skin shining and painful with edema; my
eyes bulged from my skull. I began to think about dialysis
not as a question of “if” but rather one of “when”.
Yet things slowly began to improve. Some of the news I
received was bad, if not unexpected—the kidney disease
diagnosis, the evidence of thickened airways, the near-total
failure of my pancreas to produce digestive enzymes
anymore. Other pieces of news were better—airways only
mildly thickened, lung function good and increasing, no
diabetes despite the exocrine pancreatic insufficiency,
kidney disease present but not progressing. I learned how
to manage my kidney health better—not drinking
inordinate quantities of water, managing my thirst instead
with a combination of good hydration practices and
mucus-thinning drugs, getting my medications adjusted to
avoid adverse reactions, starting on special vitamin
supplements for people with CF, staying away from
anything that could damage the blood vessels further.
As I felt the seeds of empowerment taking root, I thought
about the stories I had heard from friends online—people
living happily with their transplanted kidneys, free from
dialysis and the misery of waiting between sessions. I
thought doubly hard about my mantra from all those
years—“I’ll manage”—and wondered if perhaps that was
an appropriate way of thinking now that I was no longer
dying of a mysterious disease but rather living with a
reasonably well understood one. I moved the goalpost
accordingly—to be the oldest living person with CF,
botched diagnosis and fragmented care be damned. I had
learned that my genetics were not only atypical, but also
likely to mean that I only had problems using the CF
transmembrane conductance regulator protein rather than
producing or transporting it, which likely meant my
prognosis was better than those of many of my peers.
When the results from my renal ultrasound came back, I
thought about those too. My nephrologist gave me a
hopeful smile for the first time, saying that there was no
severe damage to the tubules or other structures in my
kidneys—just widespread inflammation and some light
scarring. And as we continued to monitor my renal
bloodwork and urine output, he said that my kidney
disease did not appear to be progressing at a rapid rate. I
contemplated the possibility of finishing out this life with
all of my original parts, save the multiple teeth I had
already lost and the gum tissue that had to be surgically
reconstructed after its destruction by years of chronic
infections. I still do not know if that hope will become
reality for me, but I realized recently that I have come to a
place in my life and health care where I can accept either
alternative. I shared that with my parents in a lengthy
series of text messages as if it were a small matter. Yet they
knew, as I did, the seismic shift it represented in my
thinking about the future.
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Advice for Clinicians Serving Patients with CF
and Kidney Disease
I share my experience now to highlight the importance of
centering patient voices in care for kidney disease, whether
related to CF or otherwise. Many people resist even
discussing organ transplantation as an option because they
have not gotten the opportunity to hear from recipients of
successful donations16. Transplant can seem like an
incredibly fatalistic prospect, especially for people who
already know they are living with terminal diseases. The
fact that your condition may take a very long time to kill
you does not, I have learned, take away the fear that comes
with thinking about potential kidney failure. I always said
that I was not afraid to die, but rather afraid to suffer; that
statement remains true for me today. I also still get regular
tastes of the suffering my CF can induce with respect to
renal function, from the recurrent infections that turn my
urine cloudy and foul to the shooting pains from
inflammation and temporary obstructions in the ducts.
Yet I have learned to think differently about suffering
itself, in terms of both the potential for a successful
physical outcome and the likelihood of emotional value
being gained by allowing the person who gave me life to
continue giving to me in that way. Perhaps most
importantly, I have learned not to look at myself as a
“waste” of any donated kidney I might receive, whether
my mother’s or a deceased person’s, because of the
progressive nature of my disease. After all, you do not get
to be the oldest living person with CF without taking a few
risks along the way—foremost among them opening your
mind to things you thought you would never consider. As
more adults with CF continue surviving into late life with
each passing year, it will be increasingly critical for
nephrology practitioners not only to understand the
challenges we face with our kidney health, but to
communicate with us about those struggles in ways that
promote empowerment. Centering our voices in that
dialogue offers a hugely impactful and readily achievable
specific aim in support of that broader goal.
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